ReviewNature reviews. Nephrology2016
Hurdles to the introduction of new therapies for immune-mediated kidney diseases.
Review in Nature reviews. Nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Efficacy of Tripterygium glycosides in immune-mediated kidney diseases as a immunomodulation drug in combination with conventional immunosuppressive agents: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- The current use of proteomics and metabolomics in glomerulonephritis: a systematic literature review.Journal of nephrology · 2024Pooled it
- Quantity and Reporting Quality of Kidney Research.Journal of the American Society of Nephrology : JASN · 2019Pooled it
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.Lupus science & medicine · 2023Trial
- Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.Annals of the rheumatic diseases · 2022Trial
- Pathological depositions in human disease: converging mechanisms in atherosclerosis, Alzheimer's disease, and related disorders.Molecular biomedicine · 2026Review
- Lupus Nephritis: Unmet Needs and Evolving Solutions.Clinical journal of the American Society of Nephrology : CJASN · 2025Review
- Article
- Glomerulonephritis: immunopathogenesis and immunotherapy.Nature reviews. Immunology · 2023Review
- Noninvasive Evaluation of Lupus Nephritis Activity Using a Radiomics Machine Learning Model Based on Ultrasound.Journal of inflammation research · 2023Article
- Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.Journal of clinical and translational hepatology · 2022Review
- Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.Pediatric nephrology (Berlin, Germany) · 2020Review
- Lupus nephritis.Nature reviews. Disease primers · 2020Review
- The Glomerular Disease Study and Trial Consortium: A Grassroots Initiative to Foster Collaboration and Innovation.Kidney international reports · 2019Review
- Re-biopsy in lupus nephritis.Annals of translational medicine · 2018Article
- CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease.Nature reviews. Nephrology · 2018Review
- Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study.Scientific reports · 2018Article
- Lupus community panel proposals for optimising clinical trials: 2018.Lupus science & medicine · 2018Review
- A systems approach to renal inflammation in SLE.Clinical immunology (Orlando, Fla.) · 2017Review
- Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Innovative immunotherapies continue to markedly benefit many disciplines in clinical medicine but disappointingly, these benefits have not translated to the treatment of kidney diseases despite encouraging findings from preclinical models of kidney dysfunction. This lack of progress in nephrology might relate to the unique biology of the kidney. More likely, this lack of progress relates to conceptual hurdles in the application of newer therapies to renal disease. In this Review we discuss seven hurdles that must be addressed in order to appropriately assess and introduce immunologic therapies for immune-mediated kidney disease: the use of appropriate criteria to define disease categories; issues relating to the heterogeneity of kidney diseases and how this heterogeneity affects approaches to treatment; issues related to the rarity of most kidney diseases; the paucity of good animal models of human kidney disease; issues relating to trial design; problems with current approaches to the identification and use of appropriate and feasible study end points; and a lack of adequate biomarkers of intrarenal inflammation and parenchymal injury. We suggest that overcoming these hurdles, in addition to searching for better therapeutic targets, will be necessary to progress the treatment of immune-mediated kidney disease into a new age of drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.